大黄(庶虫)虫丸抗大鼠免疫性肝纤维化研究  

Experimental Study of Dahuang Zhechong Pill (DHZC) in Treatment of Liver Fibrosis

作　　者：孙克伟[1] 褚裕义[1] 陈翔[1] 谢凤瑛[1] 刘伟士[1] 

机构地区：[1]湖南中医学院附属第一医院,长沙410007

出　　处：《中西医结合肝病杂志》1997年第2期90-92,共3页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

基　　金：国家"八五"科技攻关项目(85-919-04-02)

摘　　要：目的:研究大黄廑虫丸预防和治疗肝纤维化的作用。方法:运用牛血清白蛋白致大鼠免疫损伤性肝纤维化模型,观察大廑黄虫丸对肝组织病理学、肝组织羟脯氨酸(HyP)和血清透明质酸(HA)及肝功能的影响,并设秋水仙碱作对照。结果:大黄廑虫丸预防和治疗组肝纤维化率分别为72.7％和71.4％,而模型组和秋水仙碱组肝纤维化率为92.3％～100％,尤其是大黄廑虫丸治疗试验组肝HyP含量下降最显著,与模型组比较,P<0.05。结论:大黄廑虫丸有一定的抗肝纤维化作用,尤适用于对肝纤维组织的降解。Objective To study the effect of DHZC on liver fibrosis. Methods Inutmo-injured fibrosis in rate was indued by bovine serum albmin and DHZC was given during and after model production respectively Hepatic collagen contents, pathology of liver and serum hs luronic acid, transeminase were observed using colchicine as control. Results Liver fibrosis rate of DHZC group during and after model prodnction wer 72.67% and 71. 4% respectively, whereas, the untreated and colchicine groups' were 93. 3%-100%. There was a remarkable decrease of hepatic collagen contents of DHZC in after model production group,compared with the untreated(P<0. 05). Conclusion Therapeutical use of DHZC could reverse liver fibrosis to some extent.

关 键 词：大黄Zhe虫丸 中药品 肝纤维化 免疫性 

分 类 号：R286.55[医药卫生—中药学] R259.752[医药卫生—中医学]